Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies

Phase 1 Completed 46 enrolled Dana-Farber Cancer Institute Brigham and Women's Hospital · collab Massachusetts General Hospital · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find the highest dose of the combination of taxotere, cisplatin and CPT-11, that can be given without causing severe side effects. We also want to test the safety of this drug combination and see what effects (good and bad) it has on patients with advanced cancer for which there is no known curable treatment.

Timeline

Start: 1999-09
Primary completion: 2003-01
Completion: 2009-04

Publications

Results Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Earle CC, Kulke MH, Meyerhardt JA, Blaszkowsky LS, Zhu AX, Fidias P, Vincitore MM, Mayer RJ, Fuchs CS. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol. 2009 Mar;20(3):475-80. doi: 10.1093/annonc/mdn658. Epub 2009 Jan 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cisplatin	Other / unclassified	—	Intravenous
Subject	Docetaxel	Small molecule	—	Intravenous
Subject	Irinotecan	Small molecule	—	Intravenous

Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies

Summary

Timeline

Publications

Drugs

Indications